UCB Links With Daiichi Sankyo For Epilepsy In Japan
This article was originally published in PharmAsia News
Executive Summary
UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.